TORONTO, Aug. 23 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; Amex: PME) today announced that an abstract entitled, 'Galactose oxidase
Schiff's reactivity is higher in nipple aspirate fluid from cancerous breasts
than from healthy patients' has been accepted for presentation at the 30th
Annual San Antonio Breast Cancer Symposium (SABCS). The SABCS is a leading
international symposium for physicians and healthcare researchers involved in
breast cancer research.
"We are extremely pleased and honored that this abstract has been
accepted for presentation at this influential symposium," said Brent Norton,
president and chief executive officer of PreMD Inc. "This study provides
valuable clinical insight as to how women with unilateral breast cancer may
benefit from testing with galactose oxidase Schiff's (GOS) reactivity. This
presentation further strengthens our clinical data and our entire cancer
franchise, which we are progressively developing."
GOS reactivity is significantly different between nipple aspirate fluid
(NAF) taken from cancerous versus non-cancerous breasts of women with
unilateral breast cancer. This study extends these findings and evaluates GOS
reactivity in healthy control patients.
The lead author on the study is Dr. Anees B. Chagpar from the University
of Louisville. The San Antonio Breast Cancer Symposium takes place on December
13-16, 2007, in San Antonio, Texas.
About PreMD Inc.
PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products are branded as PREVU(*) Skin
Cholesterol Test, to be marketed and distributed by AstraZeneca. The company's
cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer
test. PreMD's head office is located in Toronto, Ontario and its research and
product development facility is at McMaster University in Hamilton, Ontario.
For further information, please visit www.premdinc.com. For more information
about PREVU(*), please visit www.prevu.com.
This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the success of a plan for regaining compliance with certain continued
listing standards of the American Stock Exchange, successful development or
marketing of the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating profit and
availability of funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, product liability, reliance on
third-party manufacturers, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions.
In addition, while the Company routinely obtains patents for its products
and technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
%SEDAR: 00007927E %CIK: 0001179083
For further information:
For further information: Brent Norton, President and CEO, Tel: (416)
222-3449 ext. 22, Email: firstname.lastname@example.org; Ron Hosking, Vice President
Finance and CFO, Tel: (416) 222-3449 ext. 24, Email: email@example.com;
Michelle Rabba, Manager, Corporate Communications, Tel: (416) 222-3449 ext.
25, Email: firstname.lastname@example.org